SCHEMBL839727

SCHEMBL839727

CCOC[C@H](O)C(=O)Nc1ccc(Cl)cn1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.59
MAPK1 P28482 2/20 0.59
TSHR P16473 2/20 0.55
PTK2 Q05397 1/20 0.52
TDP1 Q9NUW8 1/20 0.51
MAPT P10636 4/20 0.50
NPC1 O15118 4/20 0.50
ALDH1A1 P00352 3/20 0.50
GLA P06280 1/20 0.50
RAB9A P51151 4/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
TP53 P04637 1/20 0.49
CYP1A2 P05177 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2C19 P33261 1/20 0.49
LMNA P02545 2/20 0.48
NFKB1 P19838 1/20 0.48
CASP3 P42574 1/20 0.48
NFKB2 Q00653 1/20 0.48
RELA Q04206 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL839728 1.00 L3MBTL1 (0.59) L3MBTL1MAPK1TSHRPTK2TDP1
SCHEMBL839483 0.85 RAB9A (0.53) L3MBTL1MAPK1MAPTNPC1ALDH1A1
SCHEMBL838720 0.85 RAB9A (0.53) L3MBTL1MAPK1MAPTNPC1ALDH1A1
SCHEMBL839427 0.81 GCK (0.49)
SCHEMBL839426 0.81 GCK (0.49)
SCHEMBL839101 0.78 GCK (0.45) L3MBTL1MAPK1TSHRMAPTKDM4E
SCHEMBL839100 0.78 GCK (0.45) L3MBTL1MAPK1TSHRMAPTKDM4E
SCHEMBL839642 0.77 L3MBTL1 (0.51) L3MBTL1MAPK1TSHRPTK2TDP1
SCHEMBL839643 0.77 L3MBTL1 (0.51) L3MBTL1MAPK1TSHRPTK2TDP1
SCHEMBL850246 0.77 L3MBTL1 (0.51) L3MBTL1MAPK1TSHRPTK2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143263-B2 Therapeutic agents ASTRAZENECA AB (SE) 2012-03-27 US disclosed
US-8143263-B2 Therapeutic agents ASTRAZENECA AB (SE) 2012-03-27 US disclosed
US-8143263-B2 Therapeutic agents ASTRAZENECA AB (SE) 2012-03-27 US disclosed
EP-2324028-A2 THERAPEUTIC AGENTS 414 AstraZeneca AB (SE) 2011-05-25 EP disclosed
US-20100093757-A1 THERAPEUTIC AGENTS 414 ASTRAZENECA AB (SE) 2010-04-15 US disclosed
US-20100093757-A1 THERAPEUTIC AGENTS 414 ASTRAZENECA AB (SE) 2010-04-15 US disclosed
US-20100093757-A1 THERAPEUTIC AGENTS 414 ASTRAZENECA AB (SE) 2010-04-15 US disclosed
WO-2010015849-A2 THERAPEUTIC AGENTS 414 ASTRAZENECA AB (SE) 2010-02-11 WO disclosed
WO-2010015849-A2 THERAPEUTIC AGENTS 414 ASTRAZENECA AB (SE) 2010-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093757-A1 THERAPEUTIC AGENTS 414 GCK, GCKR, GPR119 L3MBTL1 3818/4885MAPK1 569/4885TSHR 1264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.